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Due to organ shortage and diﬃculties for availability of cadaveric donors, living donor transplantation is an important choice
for having allograft. Live donor surgery is elective and easier to organize prior to starting dialysis thereby permitting preemptive
transplantation as compared to cadaveric transplantation. Because of superior results with living kidney transplantation, eﬀorts
including the usage of “Medically complex living donors” are made to increase the availability of organs for donation. The term
“Complex living donor” is probably preferred for all suboptimal donors where decision-making is a problem due to lack of
sound medical data or consensus guidelines. Donors with advanced age, obesity, asymptomatic microhematuria, proteinuria,
hypertension, renal stone disease, history of malignancy and with chronic viral infections consist of this complex living donors.
This medical complex living donors requires careful evaluation for future renal risk. In this review we would like to present the
major issues in the evaluation process of medically complex living kidney donor.
1.Introduction
Advances in immunosuppressive therapy, reﬁnement in sur-
gical techniques and in public awareness, altruism, and
goodwillhaveallowedanincreaseinthenumberoflivingdo-
nor kidney transplantation; whereby, virtually all biological
related, unrelated and medically and psychosocially suitable
individuals can be considered as donors [1–6]. Live donor
surgeryiselectiveandeasiertoorganisepriortostartingdial-
ysisthanwhentherenaldonorisacadaver.Inaddition,living
donor transplants have the advantage of being performed
with minimal delay, thereby permitting preemptive trans-
plantation (transplantation prior to dialysis). There is also
increasing evidence that patients who undergo preemptive
transplantation have improved graft survival compared to
thosewhoundergoaperiodofdialysisbeforetransplantation
[7]. Because of superior results with living kidney trans-
plantation, eﬀorts including the usage of “medically complex
living donors” are made to increase the availability of organs
for donation [8]. The term “complex living donor” was used
ﬁrst by Reese et al. [9] in the International Forum on the
Care of the Live Kidney Donor which was held on April
2004 in Amsterdam [7] .T h eo b j e c t i v eo ft h i sm e e t i n gw a st o
develop international consensus on the standard of care and
deﬁne the responsibility of the transplant community for the
live kidney donor [7–9]. The term “complex living donor” is
probably preferred for all suboptimal donors where decision
making is a problem due to the lack of sound medical data
or consensus guidelines. After this meeting, complex living
donors were categorized based on certain risk factors (Table
1).Theriskofend-stagerenaldisease(ESRD)incomplexliv-
ingdonorsisnotclearyet.Theevaluationofapotentialrenal
allograft in living donors varies from country to country. In
this review we would like to present the major issues in the
evaluationprocessofmedicallycomplexlivingkidneydonor.
1.1. Informed Consent. First of all, to avoid conﬂict of
interests, the proposed donor should be carefully evaluated
by a physician not involved in the care of the proposed
recipient. The physician must conﬁrm that the patient’s wish
to donate is voluntary. Informed consent is a core value in
living kidney donation. Prior to donor nephrectomy, the
potential donor must be informed of [10] the following.
(i) The nature of the evaluation process.
(ii) The results and consequences/morbidity of testing,
including the possibility that the conditions that may2 Journal of Transplantation
Table 1: Risk factors associated with complex living donor.
Type of risk factor Example
Evidence of current renal disease Hematuria, proteinuria, nephrolithiasis
Direct risk for CKD Hypertension, obesity
Reduced nephron mass Age ≥ 65 years
Genetic risk factor Family history of ESRD in 1st relative
Risk factors for a CKD Diabetes in ﬁrst degree relative, impaired fasting glucode
Cardiovascular risk factors Smoking, hyperlipidemia, hypertension
Other Black race, sickle trait
Combination of previous factors Hypertensive black patient
CKD: chronic kidney disease and ESRD: end stage renal disease.
be discovered can impact future healthcare, insurabi-
lity, and social status of the potential donor.
(iii) Therisksofoperativedonornephrectomy,asassessed
after the complete evaluation. These should include,
but not be limited to the risk of death, surgical mor-
bidities, changes in health and renal function, im-
pact upon insurability/employability, and unintend-
ed eﬀects upon family and social life.
(iv) The responsibility of the individual and the social
system in the management of discovered conditions
(e.g., if the donor is discovered to have tuberculosis,
thedonorshouldundergotreatment,thecommunity
has a responsibility to help the donor secure proper
care with referral to an appropriate physician).
(v) Theexpectedtransplantoutcomes(favorableandun-
favorable) for the recipient and any speciﬁc recipient
conditions which may impact upon the decision to
donate the kidney.
(vi) Disclosure of recipient speciﬁc information which
must have the assent of the recipient.
(vii) Alternative renal replacement therapies available to
the potential recipient.
Additionally, the potential donor should be capable of
understandingtheinformationpresentedintheconsentpro-
cess.
2. ClinicalAssessment of MedicallyComplex
LivingKidney Donor
2.1. Elderly Living Donors. Previously, older kidney donors,
such as those over 50 years of age, were not considered as
suitable. However, the kidneys from such donors are now
commonly used if these individuals are in good physical and
mental condition and have adequate kidney function. A sur-
vey of kidney transplant centers in the United States in 2007
showed that almost 60 percent of centers had no upper-age
limitforkidneydonors[11].However,theinﬂuenceofdonor
age on the outcome of living donor kidney transplantation
is not clear yet. In a retrospective study by Kumar et al.
[12], the long-term outcomes of 112 recipients of kidneys
fromelderly(>55years)livingrelateddonorswerecompared
with 87 recipients who had younger donors (<45 years). The
graft and patient survival rates were similar at one year and
ﬁve years after transplantation between the two groups [12].
There was also no additional morbidity or deterioration of
preoperative blood pressure (BP) and renal function at one
year in the elderly donors. Another study from the Mayo
Clinic by De La Vega et al. [13] also showed similar results.
Overall graft survival, patient survival, and death-censored
graft survival at three years did not diﬀer signiﬁcantly
betweentherecipientsofolder(>50years)andyounger(<50
years) living donor kidney grafts [13]. However, there were
also studies that reported conﬂicting results [14, 15]. In these
studies, signiﬁcantly poorer graft survival rates were found
in kidney transplant recipients from elderly donors [14, 15].
In an analysis of 2.540 living donor kidney transplants at
the University of Minnesota, Matas et al. [16] identiﬁed
donor age greater than 55 years to be a signiﬁcant risk factor
for late graft loss. Advanced age can increase the risk for
perioperative complications, but there is no data on long-
term outcomes for this speciﬁc group in the literature [17].
2.2. Obesity. Obesity (BMI > 30kg/m2) in proposed living
donors is associated with increased risk for surgical com-
plications as well as future medical problems including dia-
betes, hypertension, nephrolithiasis, glomerular disease with
associated albuminuria or overt proteinuria, and ESRD [18–
20]. The relative risk for developing ESRD is threefold for a
BMI between 30 and 35kg/m2 and nearly ﬁvefold for a BMI
of 35–40kg/m2 [18–20]. The following consensus guidelines
regarding obese donors were suggested at the Amsterdam
Forum on the Care of the Live Kidney Donor [7].
(i) Patients with a BMI > 35kg/m2 should be discour-
aged from donating, especially when other comorbid
conditions are present.
(ii) Obese patients should be encouraged to lose weight
prior to kidney donation and should be advised not
to donate if they have other associated comorbid
conditions.
(iii) Obese patients should be informed of both acute
and long-term risks, especially when other comorbid
conditions are present.
(iv) Healthy lifestyle education should be available to all
living donors.Journal of Transplantation 3
According to our transplantation protocol we also advise
lifestyle modiﬁcations including diet and exercise to our
obese donor candidates.
2.3. Living Donors with Asymptomatic Microhematuria.
Urine dipstick testing in the absence of fever, trauma, men-
struation, or intensive exercise should be repeated twice to
conﬁrm the presence of microscopic hematuria. Isolated
microscopic hematuria (deﬁned as >3–5 urinary sediment
red blood cells (RBCs)/HPF) may not be a contraindication
todonation.RBCswithglomerularoriginhaveadysmorphic
appearance observed by phase-contrast microscopy and au-
tomated RBC analysis. Patients with persistent microscopic
hematuria should not be considered for kidney donation un-
less urine cytology and a complete urologic work up are per-
formed [7]. If urological malignancy and stone disease are
excluded, a kidney biopsy may be indicated to rule out glo-
merular pathology such as IgA nephropathy. Additionally,
Suzuki et al. reported the presence of latent mesangial IgA
deposits in approximately 16% of biopsies obtained at the
time of transplantation from both living and deceased do-
nors otherwise considered healthy [21].
2.4. Living Donors with Proteinuria. Proteinuria greater than
250mg is a marker of glomerular pathology and renal
disease. Proteinuria should be assessed as a standard part
of the donor evaluation process. The collection should be
repeated and its accuracy checked when the result is abnor-
mal. An overestimate of proteinuria should be suspected if
total urine creatinine-to-body-weight ratios are greater than
25mg/kg (>20µmol/kg), especially in those with low muscle
mass. Various laboratories have diﬀerent normal values of
quantitated urine protein, but a consensus was reached in
Amsterdam forum to conclude that a 24-hour urine protein
of >300mg is a contraindication to donation [7]. Forum
participants also concluded that microalbuminuria deter-
mination may be a more reliable marker of renal disease,
but its value as an international standard of evaluation for
kidney donors has not been determined. The presence of
microalbuminuria should preclude donation.
2.5.HypertensiveLivingDonors. Hypertensionhasbeencon-
sidered to be a contraindication in potential renal transplant
donors. However, the precise risk to donors who have bord-
erline elevation in BP and those with a family history of
hypertension has not been conclusively determined. In gen-
eral,screeningforhypertensioninapotentialdonorincludes
BPmeasurementonthreeseparateoccasions[7,22].Accord-
ingtotheguidelinebyJointNationalCommittee(JNC7),BP
shouldpreferablybemeasuredbyambulatorybloodpressure
monitoring (ABPM) [22]. Most transplant centers exclude
prospective donors with BP ≥ 140/90mmHg by ABPM from
donation. An echocardiogram may be considered to evaluate
for cardiac hypertrophy in cases with borderline high BP
or abnormalities suggesting cardiomegaly or left ventricular
hypertrophy on chest radiograph or electrocardiogram, res-
pectively. Some patients with easily controlled hypertension
who meet other deﬁned criteria (e.g., ≥50 years of age, GFR
≥ 80mL/min, and urinary albumin excretion < 30mg/day)
may represent a low-risk group for development of kidney
disease after donation and may be acceptable as kidney
donors [7]. The following consensus guidelines regarding
hypertensive donors were adopted at the Amsterdam Forum
on the Care of the Live Kidney Donor [7].
(i) Patients with a BP > 140/90mmHg by ABPM are
generally not acceptable as donors.
(ii) BP should preferably be measured by ABPM, partic-
ularly among older donors (≥50 years) and/or those
with high oﬃce BP readings.
(iii) Some patients with easily controlled hypertension
who meet other deﬁned criteria (e.g., >50 years of
age, GFR ≥ 80mL/min, and urinary albumin excre-
tion < 30mg/day) may represent a low-risk group
for development of kidney disease after donation and
may be acceptable as kidney donors.
(iv) Donors with hypertension should be regularly fol-
lowed by a physician.
2.6. Living Donors with Diabetes Mellitus. Type 2 diabetes
mellitus is an increasingly common cause of ESRD. When
the recipient has diabetes mellitus, the risk of related donors
developing diabetes later in life is a major concern. All
potential living donors should have a fasting plasma glucose
estimation to exclude undiagnosed diabetes or glucose
intolerance. Most transplantation centers regard established
diabetes mellitus as a contraindication to living donation,
and many centers exclude individuals deemed as high risk.
Although little is known as to whether single-kidney status
would accelerate the progression of diabetic nephropathy,
there were experimental studies suggesting the increased
risk of developing diabetic nephropathy after nephrectomy
[23]. A study by Silveiro et al. [24] also suggested that
nephrectomy in a patient with type 2 diabetes might increase
the progression of disease and microalbuminuria. Another
study by Seaquist et al. [25] reported increased risk for
the development of diabetic nephropathy in the relatives of
patients with diabetic nephropathy (type I). The protocol in
our institution is to advise lifestyle modiﬁcations including
weight control, diet, exercise, and tobacco and excessive
alcohol avoidance to proposed donors with impaired fasting
glucose, impaired glucose tolerance, and other risk factors.
High risk factors for developing type 2 diabetes include
those with a familial history, a BMI of ≥30kg/m2,w o m e n
with the history of gestational diabetes, and excessive alcohol
use. All other potential living kidney donors related to
recipientswithdiabetesmayalsohaveapreexistingincreased
risk of developing diabetes and diabetic nephropathy [26].
According to International Amsterdam forum on living
donor care, individuals with a history of diabetes or fasting
blood glucose of ≥126mg/dL (7.0mmol/L) on at least
two occasions (or 2-h glucose with OGTT ≥ 200mg/dL
(11.1mmol/L)) should not donate [7]. However, there was
also no comment in this forum about the acceptance of any
related donor of a patient with diabetic nephropathy [7].4 Journal of Transplantation
2.7. Living Donors with Renal Stone Disease. Ah i s t o r yo f
urinary tract stones is at least a relative contraindication to
donation because urinary system stones tend to recur and
may cause obstruction of a solitary kidney. However, renal
transplantations performed from donors with kidney stones
were reported previously [27–29]. According to Amsterdam
forum an asymptomatic potential donor with a history of a
single stone may be suitable for kidney donation if [7]h e
possessed the following characteristics.
(i) No hypercalciuria, hyperuricemia, or metabolic aci-
dosis.
(ii) No cystinuria or hyperoxaluria.
(iii) No urinary tract infection.
(iv) Multiple stones or nephrocalcinosis are not evident
on computed tomography (CT) scan.
Contraindications to donation in individuals with uri-
nary stones are (1) nephrocalcinosis on X-ray or bilateral
stone disease; and (2) stone types that have high recurrence
r a t e sa n da r ed i ﬃcult to prevent, such as the following.
(i) Cystine stones that have a high rate of recurrence and
a need for urologic procedures in the donor.
(ii) Struvite stones or infection stones that are diﬃcult
to eradicate, and thus it is not feasible to transplant
a kidney with them into an immunosuppressed
patient.
(iii) Stones associated with inherited or other systemic
disorders, such as primary or enteric hyperoxaluria,
distal renal tubular acidosis, and sarcoid because of
the probability of a high rate of recurrence and the
risk of renal insuﬃciency.
(iv) Stones in the setting of inﬂammatory bowel disease
with an increased risk of stones particularly after
bowel resection, also increased risk of renal insuﬃ-
ciency.
(v) Recurrence while on appropriate treatment (i.e.,
failed therapy).
Asymptomatic potential donor with current single stone
may be suitable if [7]
(i) the donor meets the criteria shown previously for
single stone formers and current stone is ≤1.5cm
in size or potentially removable during transplant.
An asymptomatic potential donor with no history of
calciluria or colic event is found to have a single stone
on evaluation may be suitable for kidney donation if
[7];
(i) no metabolic abnormality or urinary infection exists
and if multiple stones or nephrocalcinosis are not
evident on CT.
Incidental renal stone detected by magnetic resonance
or computerized tomography renal angiography is relatively
common (7.4%) in the report from the single center by
Kim et al. [30]. Authors reported that kidneys from donors
withsmall(medianradius:2mm)andnonobstructivestones
could be acceptable provided with normal metabolic studies.
Another important point is the age of the donor. Younger
patients have a longer exposure to risk of recurrence. A stone
initially detected in a person older than 50 years is unlikely
to recur. In contrast, the risk for stone recurrence is higher in
donor candidates aged 25–35 years and must be considered
during the evaluation process of donors [7, 29].
2.8. Living Donors with History of Malignancy. Kidney donor
candidates should be screened for both personal and family
history of malignancy. They should undergo standard age-
and gender-appropriate screening tests as recommended by
national organizations. A prior history of the following ma-
lignancies usually excludes live kidney donation [7].
(i) Melanoma, testicular cancer, renal cell carcinoma,
choriocarcinoma, hematological malignancy, bron-
chial cancer, breast cancer, and monoclonal gam-
mopathy [31–34].
Apriorhistoryofmalignancyusuallyexcludeslivekidney
donation but may be acceptable if [7].
(i) The speciﬁc cancer is curable and the potential trans-
missionofthecancercanreasonablybeexcluded.Ex-
amples include colon cancer (Dukes A, >5y e a r sa g o ) ,
nonmelanoma skin cancer, or carcinoma in situ of
the cervix.
An oncology consultation is also advised to donor can-
didates with a history of malignancy during the donor eval-
uation process.
2.9.LivingDonorswithChronicViralInfections. HIVpositive
status is a contraindication for donation. Donor with a po-
sitive hepatitis C Virus (HCV) serology may be only consid-
ered for donation to a HCV positive recipient, if the donor
PCR is negative, certain genotypes (genotype 4) are treated
and eradicated from the donor, and there is no evidence of
chronichepatitis orcirrhosis onliverbiopsy. Thereisnodata
on live kidney transplantation from HCV positive donors;
however,cadavericrenaltransplantationsfromHCVpositive
donors to HCV positive recipients were reported [35]. In this
report, concerns regarding HCV superinfection if a diﬀerent
HCV genotype of a positive donor is transmitted to a re-
cipient were also stated [35].
Although the detection of hepatitis B surface antigen
(HBsAg) in a potential kidney donor generally excludes the
individual from live kidney donation [36]. In our unit, living
related kidney transplantations from donors with a positive
HBsAgtoHBVnegativerecipientswereperformedwithlam-
ivudin prophylaxis when the donor is HBV DNA PCR nega-
tive and the recipient’s anti-HBS titer is > 100mIU/mL.
Another important point is that even if HBsAg is negative,
screening for HBV core total antibody (IgM and IgG) should
be performed to exclude low levels of HBsAg and escape
mutants of HBV not detectable by the current screening
assays for HBsAg [7].Journal of Transplantation 5
2.10.LivingDonorswithHistoryofTuberculosis. Tuberculosis
is a common infection of renal transplant recipients in devel-
oping countries. The peak incidence is after the ﬁrst year of
transplantation and mortality is considerable [37]. Active
Mycobacterium tuberculosis infection is a contraindication
for donation because tuberculosis has been transmitted from
live kidney donors to their recipients [38]. Although in
some centers a past history of pulmonary tuberculosis is a
relative contraindication to donation, many kidney trans-
plantations were performed from donors with a past history
of pulmonary tuberculosis in several transplant centers as
well as in our unit. Some authors suggested that a positive
puriﬁed protein derivative (PPD) test due to Bacille Ca-
lmette-Gu´ erin vaccination may not be helpful to screen a
potentiallivekidneydonor.However,astudyfromourcenter
reported no tuberculosis in renal transplant recipients who
had INH prophylaxis for 1 year after transplantation because
their and the donors’ PPD skin test reading was greater
than 10mm of induration [37]. In our unit, donation of in-
dividuals with a past history of pulmonary tuberculosis is
also acceptable. Although there is no clear evidence in the
literature for preventing reactivation of tuberculosis and risk
of liver toxicity, 1-year INH prophylaxis could be admin-
istered to kidney recipients from these donors and recipients
with past history of tuberculosis.
Urinary tuberculosis is a contraindication for donation.
Additionally, in Amsterdam forum it was suggested that do-
nors previously treated for urinary tuberculosis might have
dormant tuberculosis within the kidney and thus remain
unsuitable for donation [7].
3. Conclusion
Because of superior results with living kidney transplanta-
tions, eﬀorts including the use of “medically complex living
donors” are made to increase the availability of organs
for donation. However, in the evaluation process of these
proposed donors we should not forget the following four
issues: (1) the risk to the donor must be low, (2) the donor
must be fully informed, (3) the decision to donate must
be independent and voluntary, and (4) there must be good
chance of a successful recipient outcome [39].
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